NPN inhibitors refer to a class of chemical compounds known for their ability to interact with and inhibit the function of NPN (non-polar naphthyl) sites within various biological systems. These compounds are often characterized by their hydrophobic properties and aromatic structures, which allow them to fit into the hydrophobic pockets of target molecules. The inhibition mechanism typically involves the binding of the inhibitor to a specific active site or allosteric region of the target protein, thereby blocking its normal activity. This binding often leads to conformational changes in the protein structure, impacting its function. The exact structure of NPN inhibitors can vary greatly, but they generally share a core hydrophobic scaffold, which is crucial for their binding and inhibitory action. The diversity in their structures allows for the fine-tuning of their interaction with specific targets, leading to varying levels of affinity and specificity.
Structurally, NPN inhibitors are often built around a naphthyl core or similar aromatic hydrocarbon frameworks that confer non-polarity. This allows them to engage in hydrophobic interactions, which are a key element in their inhibitory properties. Additionally, modifications such as side chains, substituents, or bridging moieties can enhance binding affinity and specificity for certain biological targets. These inhibitors are frequently used in research to explore protein functions, pathways, and the roles of hydrophobic active sites in biochemical reactions. The non-polar nature of NPN inhibitors often affects their solubility and interaction with different biological environments, making them valuable in the study of protein-lipid interactions, membrane-associated proteins, and other systems where hydrophobic interactions play a significant role. The structure-activity relationship (SAR) of these inhibitors is a topic of interest, as small changes to their chemical structure can significantly alter their binding and inhibitory potential.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | $31.00 $103.00 $283.00 $978.00 | 2 | |
Tranilast inhibits the release of transforming growth factor-beta (TGF-β), thereby potentially reducing the activity influenced by Nephrocan in the TGF-β signaling pathway. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 is an inhibitor of the TGF-β type I receptor ALK5, which may indirectly affect Nephrocan's regulatory role in the TGF-β signaling pathway. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
This compound selectively inhibits TGF-β receptors I and II, potentially altering Nephrocan's downstream effects in TGF-β signaling. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A-83-01 inhibits ALK5, ALK7, and ALK4, which are receptors involved in TGF-β signaling, potentially impacting Nephrocan's related activities. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $102.00 $416.00 | 6 | |
Pirfenidone has anti-fibrotic properties, likely through inhibition of TGF-β synthesis, and may indirectly affect Nephrocan's role in extracellular matrix organization. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1775.00 | ||
This agent inhibits collagen type I synthesis, a key component of the extracellular matrix, and might indirectly influence Nephrocan's function. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
As a TGF-β receptor I kinase inhibitor, Galunisertib may modulate Nephrocan's activities in the TGF-β pathway. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
SD-208 is a TGF-βRI kinase inhibitor, potentially influencing Nephrocan's interaction with the TGF-β signaling pathway. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
This chemical is another TGF-β receptor I kinase inhibitor, which may impact the TGF-β pathway activities influenced by Nephrocan. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $89.00 $275.00 | 9 | |
LY2157299 selectively inhibits TGF-β receptor I, potentially modulating the effects of Nephrocan in TGF-β signaling. | ||||||